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Is High-Tech Care in a Middle Income Country Worth It?
Evidence from Perinatal Centers in Russia
By Dzhamilya Nigmatulina†, Charles Becker‡
How much does a dramatic increase in technology improve
healthcare quality in an upper-middle income country? Using
rich vital statistics on infant health outcomes, this study evalu-
ates the effect of introducing technologically advanced perinatal
hospitals in 24 regions of Russia on infant mortality during the
period 2009-2013. A 7-year aggregate panel dataset reveals that
opening a perinatal center corresponds to infant mortality reduc-
tion by 3.8 percent from the baseline rate, neonatal (0-28 day)
mortality by 7 percent and early neonatal (0-6 day) mortality by
7.3 percent. We find that the perinatal centers help to save 263
additional infant lives annually, ranging from 3 to 25 lives in
regions with different birth rates. However, we further find that
an average cost per life saved is 52 mln rb (or 2.6 m 2014 PPP
USD), which is much higher than the cost of similar interven-
tions in the US.
JEL: I120, I180
Keywords: infant health; infant mortality; prenatal care; peri-
natal hospitals; impact evaluation; returns to technology; cost of
healthcare
At the beginning of perestroika, the Soviet government revealed that infant mortality
in the USSR was 3 to 5 times higher than in most countries in Western Europe. Today
the gap has narrowed, yet Russian infant mortality (8.7 per 1000 births in 2012) remains
higher than in Hungary, Czech Republic and Latvia. A stricter definition of a live birth
than the EU countries prior to 2012 aggravates this situation and results in many fewer
infant deaths recorded in Russian official statistics.1
Poor international rankings together with shrinking population have motivated the Rus-
sian government to increase its investment in improving demographic indicators. In De-
cember 2007 some 19 billion rb (or 471 million 2014 USD) (Ministry of Healthcare of the
Russian Federation, 2008) were invested from federal funds into building one perinatal
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drovna Kvasha, Daria Pelech, Klara Sabirianova Peter, Frank Sloan, Susan Steiner, Christopher Timmins, Maximo
Torero, Tanner Regan, Giuseppe Rossitti, Guzel Ernstovna Ulumbekova, the participants of LSE Spatial Economics
Research Center Conference and two anonymous referees for helpful comments and feedback. All errors of fact and
interpretation are our own.
† Nigmatulina: London School of Economics, d.nigmatulina@lse.ac.uk.
‡ Becker: Duke University, cbecker@econ.duke.edu.
1Russia and previously the USSR imposed a restriction on weight and gestational period for regarding a birth as
live-born, which meant eliminating the most risky cases from the statistics; many other countries have never imposed
restrictions and consequently have had higher reported infant mortality rates.
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3Figure 1. European Rankings of Infant Mortality
Note: Infant mortality in Russia is one of the highest in Europe, even in comparison to the other transition economies.
Its rank has not improved significantly over the years.
∗ Belarus value is from 2009. ∗∗ The member states that were part of the European Union by 2004.
Source: World Health Organization Europe.
center in each of 23 (out of 83) Russian regions as part of the National Health Project;
one more center was built in Omsk region (oblast) in the same period solely funded by the
local budget.2 Each centrally-funded hospital required a contribution of 10-50 percent from
the local government (Minister of Healthcare Veronika Skvortsova, quoted in Rossiiskaya
Gazeta on May 5th, 2013). Most centers opened in late 2010 and late 2011. They were
placed in oblast capitals and the citizens of the region were entitled to free services if a
mother had sufficient risk of a complicated delivery.
These state-of-the-art hospitals were intended to provide intensive care for births with
2The centers co-financed by the federal funds were Blagoveshchensk, Volgograd, Voronezh, Irkutsk, Kemerovo,
Kaliningrad, Kirov, Krasnodar, Krasnoyarsk, Kurgan, Kursk, Perm, Rostov-on-Don, Ryazan, Saratov, Saransk,
Tver, Tomsk, Chita, Yaroslavl, Murmansk, Sverdlovsk and Saint-Petersburg.
4complications, premature births, and other conditions for which a standard hospital or
maternity unit did not have the requisite facilities. Most importantly, each of the peri-
natal centers was equipped with a Neonatal Intensive Care Unit (NICU) with high-tech
machinery for resuscitating prematurely born infants. The mechanism of mortality reduc-
tion works via re-routing of potentially risky deliveries from regional maternity hospitals
to these centers (Sukhanova, 2012), thereby increasing the probability that an infant under
risk gains access to advanced infrastructure, and specifically to NICU.
The investment was carried out without rigorous economic evaluation of its potential
returns. How much did health improve from the perinatal centers alone and was it worth
it? We attempt to answer this question in our study. Since the survival of at-risk infants
in the very early ages is most dependent on availability of equipment (Cutler and Meara
(2000)), we expect to find a reduction in infant mortality overall and especially in neonatal
mortality (age 0-28 days) and early neonatal mortality (age 0-6 days). Indeed, we find that
the highest proportional reduction in mortality was for the 0-6 day category (7.3 percent
from the baseline), less for 0-28 day category (7 percent from the baseline rate) and that
there was almost no effect on deaths at 28-365 days.
In December 2013, Russian Ministry of Health initiated a program to build 32 additional
perinatal centers in 30 Russian regions at the cost of 53 billion rb (1.277 billion 2014
USD) to the federal budget (Ministry of Healthcare of the Russian Federation, 2013).3 As
before, no sufficient comparative analysis was conducted as to the effectiveness of this vast
expenditure on health outcomes. Moreover, it is overwhelmingly likely that other large
health infrastructure projects are also under contemplation, in Russia and elsewhere, with
little reliance on serious effectiveness assessments. Our study provides both a template of
how to analyze these investments and an estimate of what to expect from them.
The relevance of our study is not limited to the economic evaluation of this single policy.
While technology-intensive investments such as NICU’s have been shown to be life-saving,
the cost of each life saved is a matter of hot debate (Cutler and Meara, 2000; Almond
et al., 2010; Almond and Doyle Jr, 2011; Cutler et al., 1998). Moreover, although there is
a large body of literature estimating the returns to technology-intensive spending in first-
world countries, like the US, and returns to basic investments in developing countries, like
Tanzania, the evidence regarding any health interventions in middle-income countries is
quite scarce. Further, by focusing on a middle income country, we benefit from evaluating
the setting where the entire population has access to basic elements of care, but often
limited access to advanced care: in high income countries near universally good health
outcomes make it difficult to identify the effect of technology investments, whereas in
low income countries it is hard to separate the effects of healthcare access expansion and
technology itself.
3The selected cities (all regional capitals) are Arkhangelsk, Belgorod, Bryansk, Kaluga, Lipetsk, Nizhny Novgorod,
Orenburg, Penza, Pskov, Samara, Sakhalin, Smolensk, Tambov, Ulyanovsk, Chelyabinsk, Stavropol, Krasnodar, Bar-
naul (Altaiskiy kray), Ulan-Ude (Republic of Buryatia), Ufa (Bashkortostan), Makhachkala (Dagestan), Magas (In-
gushetia), Nalchik (Kabardino-Balkaria), Petrozavodsk (Republic of Karelia), Yakutsk (Republic of Sakha-Yakutia),
Abakan (Republic of Khakassia), Moscow, 2 centers in Krasnoyarsk, 1 center in Leningradskaya oblast’ and 2 centers
in Moscovskaya oblast’.
5On the one hand, we may expect to find higher returns than in the US, as there is less
medical infrastructure at baseline. On the other hand, bottlenecks, such as a low supply
of doctors, or poor healthcare organization and infrastructure may impede the realization
of the technology in full.
We believe that our choice of data and sample can give an important and informative
estimate of the returns to costly medical advances in a middle-income country. First, low
birth weight infant care is expensive. Cutler and Meara (2000) quote a cost as high as
$3,500 per infant per day in a NICU in the US; ultimately, this can sum to as much as $1
million for a prolonged stay. Second, in middle-income countries newborns’ outcomes reflect
both the state of and changes to the healthcare system and span all income and education
groups of the population, as births outside of hospitals comprise only 0.16 percent in Russia
today (2013). Third, for extremely low and low birth weight outcomes the probability of
survival almost fully depends on the availability of technology (Paneth, 1995; Williams
and Chen, 1982; Muraskas and Parsi, 2008), whereas for other outcome variables such as
tuberculosis rates or occurrence and mortality from cardiovascular diseases, it difficult to
distinguish the relative roles of income, lifestyle, and doctor’s qualifications.
Finally, the introduction of perinatal centers with NICU’s across so many locations and
in such a short time is unprecedented. The perinatal centers opened within a sufficiently
short period (1-4 years) that many other aspects such as the composition of the population,
organization of care, and number of at-risk infants born annually could not have changed
much. Thus, our data allow us to estimate the marginal returns to the change in medical
technology (rather than the average return over a long period of time). The remaining, more
sensitive, factors include a possible increase in the number of doctors, and a ‘substitution
effect’ whereby the new centers could have detracted resources from other facilities in the
region. We explore these concerns by measuring the impact of closures of basic obstetrics
hospitals and maternity units. We further account for potential increases in the number of
neonatologists in the treated regions and attempt to estimate the heterogeneity of outcomes
from different supply thereof. We also face and address a second methodological challenge,
when some treatment coincided with a change in birth accounting in 2012. Although as the
change was country-wide, the response to the change could have been different depending
on whether the region was treated or not. By using data birth by birthweights and the
proportion of ‘late abortions’, we check whether the response to the accounting policy was
significantly different in the treated regions vs. untreated and confirm that this was not
the case.
The paper is organized as follows. Section I provides background on the policy and
the relevance of the study, Section II reviews prior literature on returns to healthcare
investment, Section III briefly outlines the mechanism of reducing mortality, Section IV
describes the variables, Section V outlines the empirical model and validity checks, Section
VI presents the lifesaving effect of the perinatal centers and evaluates it against their costs
of construction and maintenance, and Section VII concludes.
6I. Background
A. Perinatal Care in Russia
Every Russian woman in childbirth is entitled to free care during delivery regardless
of the type of hospital, be it high or basic, at which she presents herself. She will be
referred for delivery in a perinatal center if she is designated as at risk for a complicated
delivery. Perinatal centers on average hosted 22.9 percent of all births in the country in
2012 (Starodubov and Sukhanova, 2013). A perinatal center mainly differs from other
obstetrics facilities by being equipped with an NICU and providing the latest available
technologically intensive care for infants. Even before the expansionary policy was enacted,
perinatal centers targeting complicated deliveries existed in 54 regions, but they generally
were not as technologically advanced as the new ones (we later test whether the presence
of a perinatal center in the region yields a different result than if the high-tech facility is
introduced for the first time).
B. Mortality Statistics in Russia
Until 2012, Russia had higher gestation time and birth weight thresholds for reporting
live and stillbirths than in most European countries. Such rules not only meant reporting
lower infant deaths than under conventional WHO definitions, but it also made it fairly
easy to recategorize some marginal delivery cases into groups that were less significant for
national statistics (stillbirths) or not accounted at all by official statistics (‘late abortion’
or ‘miscarriage’).
In 2012 the official threshold for registering a birth as a ‘live birth’ was moved from
the 1000g minimum weight and 28 weeks minimum gestation down to 500g and 22 weeks,
respectively. Naturally, these changes caused the reported mortality to rise (as shown in
Appendix Figure A1). As for misreporting (due to category transfers), it is likely to have
shrunk, but potentially remained an important concern just around the new threshold:
marginal births at 22-23 weeks of pregnancy (or births of live infants weighing 500-700g).
Details of definitional changes and likely impacts on recorded values are provided in the
Online Appendix. Another type of undercounting may have become widespread in the
meantime: at any weight or gestational age fragile infants who die very soon after birth
often may be characterized as stillbirths, since stillbirths is a statistic less scrutinized by
domestic and international public health officials.
Undercounting is only a threat to validity in our difference in difference design if the
degree of undercounting changes after treatment. We thus focus on dynamics of under-
counting in each region to ensure it does not affect the validity of our results. The concern
may arise if, for example, obstetricians in the treated region are directed to misreport in-
fant deaths in order to show improvements attributed to the perinatal center. By using
the internal Ministry of Healthcare records of countrywide births by weight, in the Online
Appendix we investigate whether bunching of birth records at the unaccounted categories,
or categories just above the relevant threshold (1000g prior to 2012 and 500g post 2012)
7have shrunk. We rule this concern out by showing that there is no relative change in
bunching (or shrinking) after treatment.
II. Prior Literature
Interventions that save infant lives can vary greatly in their costs and their effectiveness,
depending on the baseline level of health and the intensity of the investments. The literature
to date concentrates primarily on costly high-tech interventions in the US and low-cost
interventions in developing and middle-income countries (or historical data for developed
countries).4
The low-cost interventions included training traditional birth attendants to refer riskier
patients to hospitals and performing basic tasks in Tanzania (Gill et al., 2011), training
male nurses in India (Bang et al., 1999), improved sanitation of water facilities for Native
American populations (Watson, 2006), and a Danish home-visiting program in the late
1930’s (Wu¨st, 2012), all of which were shown to reduce infant mortality on the order of
40-65 percent. Some low-cost interventions also have been implemented in middle-income
countries; analyses find moderate to high reductions in mortality, and high cost effective-
ness of these reductions. Nizalova and Vyshnya (2010) estimate how the ‘Mother and
Infant’ program in Ukraine, which involved training the obstetrics personnel and changes
in practices, has reduced infant mortality rate by 3.13 deaths per 1000 births (23 percent
from the baseline rate). Galiani, Gertler and Schargrodsky (2005) argue that cleaner water
from privatization of water facilities saved infant lives in Argentina. New investments and
expansion of services led to improved sanitation and reduced first-month mortality by 8
percent compared to the baseline mortality rate in 1990. All these interventions are likely
to save lives of healthy infants who have normal birth weights and are not born pre-term
(for example, water sanitation only eliminates deaths from parasitic diseases caught by
otherwise healthy infants). These interventions would likely be unimportant for the pre-
maturely born, because low birth weight infants are likely to die in the first day or week
without the availability of an NICU. Thus, the target group examined here is not cov-
ered, to our knowledge, in any of the previous literature on middle-income and developing
countries.
High-tech intervention studies are concentrated in the US and are related to the analysis
of the returns to healthcare spending. The US literature shows two common findings.
Cross-sectional studies of American regions tend to indicate small or no effects of the
incremental spending in technology (Baicker and Chandra, 2004; Grumbach, 2002; Almond
and Doyle Jr, 2011; Goodman et al., 2002; Finkelstein and McKnight, 2008), or at most
moderate evidence from (Fisher et al., 2003; Almond et al., 2010; Doyle, 2011), whereas
studies concentrating over large time periods demonstrate large benefits to technologically
intensive and costly interventions (Cutler and Meara, 2000; Cutler and McClellan, 2001;
Schwarcz et al., 2000; Luce et al., 2006).
4Mangham-Jefferies et al. (2014) provides a comprehensive review of studies on delivery care interventions in
developing countries.
8Cutler and McClellan (2001) consider both treatment expansion and treatment substi-
tution when they evaluate returns to new technologies used to treat heart attacks, low
birth weight infants, depression, cataracts and breast cancer diagnosis. They demonstrate
a very large positive return to catheterization and to technologies introduced in the 1990’s
to treat LBW infants, while breast cancer screening had an indeterminate effect. Cutler,
Rosen and Vijan (2006) show that the cost of year of life saved has increased from $7,400
to $36,600 during the period 1960-2000, which still yields a positive return, as the com-
monly cited social value for a statistical year of life gained is $100,000 (Viscusi, 1993).
The authors emphasize that the return to healthcare spending remains positive for all age
groups, except for the elderly, for whom the costs for a year of life gained is $145,000,
indicating possible ‘overspending’ in US healthcare in this area. Cutler and Meara (2000)
demonstrate considerable cost effectiveness of the investment in LBW infant health by
considering both the length and the quality of life.
In our study we compare the cost effectiveness of an expensive intervention to both low-
cost interventions in middle-income countries and expensive interventions in the US. We
add to the literature by analyzing a setting in which on the one hand high-tech care is
likely to be underutilized, unlike in the US, but on the other hand there are institutional
barriers and bottlenecks in other healthcare inputs, resulting on uncertain marginal re-
turns compared to the US. Moreover, while most studies on middle-income and developing
countries focus on low-cost care and its returns, and we try to verify whether an advanced,
high-cost intervention will demonstrate superior or inferior health outcomes and at what
price.
III. Economic Mechanism
The opening of the perinatal center primarily changes ‘technology’, which is an input into
each region’s health production function. Other inputs such as regular obstetricians and
number and condition of patients are likely to be stable in the several years’ time before
and after the opening (we are able to confirm this assertion for obstetricians, neonatologists
and midwives later on). On the one hand, we anticipate that Russia had been on the steep
portion of its production function curve, and to some extent technology was underutilized
and outdated; thus, adding complex technology could improve health outcomes positively
and to a larger extent than in richer countries. At the same time, this positive effect may
be counteracted by institutional barriers and insufficient numbers of qualified doctors able
to work at the center, so that the cost of a year of life saved actually could be higher than
in the US.
The mechanism on a micro level will work through a higher probability of admission to
a NICU of infants who can benefit most from such treatment. For example, a prematurely
born infant who has a collapsed lung will only be able to survive if given an artificial
ventilation in a NICU. We regard a NICU treatment as a summary measure for procedures,
such as artificial ventilation, diagnostic ultrasound audiological screening, and operations
on the heart. Thus, once a perinatal center is open, the probability of an at-risk infant
(early term birth and/or low birth weight) of accessing a NICU increases. We expect early
9mortality level (0-6 days, 0-28 days and perinatal losses) to decrease more than mortality
in the other categories, as the group of infants who usually die in the first week survives
only through admission into a NICU.
Conversely, the occurrence of deaths in older ages (one month and more) is not expected
to change with the presence of NICU, since older infants usually are not admitted there.
Thus, such a variable can be used as a placebo test. We expect that infant mortality will
decrease overall in a treatment region because the highest risk group will be selected into
the NICU and will survive. However, only a decrease in overall (total) infant mortality
will show the true effectiveness of the technology, as the survival of the at-risk group on
average would exceed one year (as opposed to improved neonatal survival at the expense
of increased post-neonatal mortality).
IV. Variables
We run regressions with six categories of mortality rates as outcome variables for our first
specification: infant, neonatal, early neonatal and post neonatal mortality, perinatal losses,
and stillbirths. Our data are region-level and constitute a 7-year panel (2007-2013) of all
(83) Russian oblasts. Births are coded by the address of parents in most cases, whereas
deaths are more likely to be reported at the hospital address, so if any mothers choose to
go to perinatal centers outside their regions of residence, this may lead to a downward bias
through also improving the recorded outcomes in the control groups. However, traveling
to the regional capitals with perinatal centers is costly (most regional capitals are located
at the center of the region), and there are institutional barriers to giving birth outside
one’s home city or region.5 According to the expert opinion of the Chief Neonatologist of
Russia, D. N. Degtyarev, although legal, it is administrationally costly for a doctor in one
region to direct a patient to a hospital in another, which is why doctors are unwilling to
identify sufficient medical conditions for redirecting.6 So, even if it were true that some
mothers give birth outside the region they reside, the number of such mothers is likely to
be small. In order be sure, we test whether the birth counts change in the region itself and
the neighboring regions after the opening of the perinatal center and add an interaction
term for centers close to borders.
We also use additional variables, such as infants born extremely prematurely (22-27
weeks) for 2010 and 2011 and shares of births by weight for years 2010-2012 (published
in the Ministry of Health Statistics Rodovspomozhenie). As is discussed earlier, these
detailed characteristics prove useful in eliminating suspicions as to the possibility of greater
undercounting in treated regions.
We collect the first set of outcome variables for 2007-2013 for each oblast from the Cen-
tral Research Institute for Organization and Informatization of Healthcare, by reaching
out to the institute and requesting the access to restricted data. Control variables related
to healthcare directly, such as obstetrics beds provision, the number of Ob Gyn doctors
5Exceptions are Tomsk, Tyumen, Cheboksary, Ryazan and Gorno-Altaisk
6Dmitry Nikolaevich Degtyarev, e-mail message to the author (Nigmatulina), June 19, 2014
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per woman, and the percent of normal births, are collected from Rodovspomozhenie. Local
economic and transportation variables, such as income per capita (2007-2014), urban and
rural population are collected from Rosstat’s publication Regioni Rossii7. To our knowl-
edge, few if any other upper middle income countries have comparable publicly available
data.
All variables are summarized by treatment group in Appendix Tables A2-A3 and for the
overall sample across all years in Appendix Table A1. There are no significant differences
in most variables across two groups of interest: treated and to-be-treated. A few exceptions
include treated group being more urbanised, and its income per capita being slightly lower,
both of which we control for.
V. Methodology
A. Baseline Model
We use a difference in difference (DD) model to estimate the effect of introducing the
perinatal centers. The 7-year panel of 83 regions allows us to measure the Average Treat-
ment Effect (ATE); that is by how much mortality changes on average if the perinatal
center is introduced in any of the regions. Accounting for fixed differences between the
treatment and control groups (with oblast dummies) and capturing the unobserved factors
that cause changes in the health outcome even in the absence of a policy change (with
time variant controls and year dummies), we thus measure ATE with a DD approach. The
coefficient of interest multiplies the binary variable that is equal to one whenever a center
is open in that year and that region.
We account for each oblast’s time invariant (at least for 7 years) characteristics, such as
baseline wealth, population, geography, ecology and transportation network and the level
of healthcare quality, which can affect the underlying level of mortality in each region. By
adding a full set of region dummies we remove the above characteristics, including all fixed
selection criteria for treatment, such as presence of the medical university and minimum
population requirement for the regional capital.8 We account for possible serial correlation
in the error term by clustering at the oblast level(Bertrand, Duflo and Mullainathan, 2004).
This reduces the significance of our coefficients in a preferred specification from 0.05 percent
to 0.1 percent, indicating that errors are indeed likely to be positively correlated within
7Chechen Republic reported missing income per capita in 2007-2009, the three values were replaced by the value
in 2010. All regression results are robust to exclusion of the region from the sample
8According to the unpublished presentation by E. N. Baybarina (currently a department head in the Russian
Ministry of Health) an oblast is to be selected based on following criteria. If the center is to be built from scratch: 1)
shortage of neonatal emergency beds (less than 2 in a 200-300 km radius); 2) existence of a higher medical institution
with a Pediatric Department, and 3) readiness of the region to co-finance. If the center is being renovated, selection
was awarded to hospitals in which 1) the neonatal emergency room was designed to contain no less than 9 -12 beds
2) the center was planned for being built in cities with no less than 300 000 people 3) there exists a shortage of a
neonatal emergency beds, and specifically less than 2 per 1000 births in the radius 200-300 km, and 4) existence of
a university-level medical school (Dmitry Nikolayevich Degtyarev, Chief Neonatologist of Russia, email message to
author, April 16, 2014). Moreover, D. M. Degtyarev, who also is a member of the selection committee for the regions
with the perinatal center, has pointed out in the email that political factors also played a role in the selection.
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oblasts.
We should also be aware of that by using a DD estimator with aggregate data we ignore
the true sampling variability of mortality in the control oblasts, so the estimated variance
could still be too small (Besley and Case, 2000). This problem can only be solved with
more detailed data, which we lack at this point. Our primary regression is as follows:
(1) Mr,t = β0 + β1Pr,t + β2Zrt + λt + γr + εr,t
Infant mortality Mr,t at time t in region r is affected by the presence of one of the 24
perinatal centers, Prt. If the center opens in the beginning of the year, the binary variable
takes the value 1 starting from that year; if the center opens in the end of the year, which is
usually the case, the value of 1 is only assigned starting the following year, so the treatment
is correctly aligned with mortality calculated at the end of each year. In this way, one center
opened in 2009 (in Omsk), three centers became effective in 2010, 11 centers started in 2011
and another nine opened in early 2012. λt and γr are time and oblast dummy variables.
Zrt includes the set of additional region-year factors, such as non-infrastructure healthcare
spending in a region, a measure of regional prosperity (income per capita) and a measure
of social distress (recorded cases of alcoholism per capita). Our original list of controls was
longer and included other measures of social distress such as proportion of the population
below the poverty line and alcohol purchases per capita. We instead chose income per
capita as it is more informative about the overall wealth in the region, and used alcoholism
occurrence, as alcohol purchases positively correlated with wealth and thus made a poor
control for social distress.9
Importantly, we should be wary of using variables that are affected by treatment (Wooldridge,
2010, p.910). These include the number of hospital beds and number of neonatologists,
because we are unable to condition on these variables being constant and have an unbi-
ased estimator of the effect of treatment. We explore an alternative way of isolating these
possible co-moving inputs into healthcare production function in Section VI.B.
Appendix Table A5 demonstrates how our coefficient of interest changes when we se-
quentially add various fixed effects and controls. We further find that the coefficient β1 on
the key outcome variable, 0-6 day mortality, is robust to the inclusion of the oblast-specific
linear time trend. However, our preferred specification excludes a time trend, since other-
wise we are left with too few degrees of freedom to have power to estimate the effect on
other outcome variables. Finally, the intercept measure, β0, signifies the mean of the fixed
effects.
The policy variable is restricted to have the same effect every year (Wooldridge, 2010,
p. 151). We also run a sequential model (Equation 2), in which we use a set of indicators,
9The regression with the alternative controls of social distress is included in the Table A4 of the appendix, in
which the coefficients and significance remain almost the same.
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di, of one, two and up to five years after opening.
(2) Mr,t = β0 +
5∑
i=1
β1,i ∗ di ∗ Treatedr,t + β2Zrt + λt + γr + ψt + εr,t
The DD estimator in Equations (1) and (2) is valid and we can estimate the ATE, if
the mean changes in the no-program outcome measures are the same for participants and
nonparticipants (Heckman, LaLonde and Smith, 1999):
(3) E(Y0t − Y0t′ |D = 1) = E(Y0t − Y0t′ |D = 0)
If present, bias could be caused by a non-random selection of the treatment and control
groups leading to the differential trends in the absence of treatment. We address this issue
with the methods discussed below.
B. Test for Pre-Existing Trends and for Other Policies
If the regions receiving hospitals are developing more rapidly at the time of treatment,
they would have a steeper mortality reduction trend and the policy impact may be overesti-
mated. As the financing of a center is done via a matching grant with both federal and local
funds, the average of 20 percent from local funds requirement to co-finance the investment
increases the chances of a grant to be awarded to richer areas. Therefore, a wealthier oblast
with a larger local budget might have more to spend on other infrastructure and amenities
around the center, such as roads and doctor’s salaries and benefits, improving mortality
more even in the absence of treatment. In short, the treated oblasts might get the center
because they can make it work. This would make condition in equation (3) fail and bias
the estimate of the policy effect, but the direction is unclear. Better administration could
lead to more lives saved, but location in wealthier regions that already have relatively good
facilities could have the reverse effect.
Another source of potential selection bias is the possibility that federal government gave
preference to locations in the greatest need of a center, namely places with high congestion
in obstetrics units, long queues, or old facilities. Thus, the marginal returns to a center
would be higher on average than in the control oblasts, working in addition via expansion
of basic facilities and not just improving the technology input.
A formal method to test whether the mortality trends in the absence of policy would have
been the same in the treatment and control group is to allow the to-be-treated regions to
evolve along a different time trend before the policy. In other words, this test is to regress
the mortality variables on overall time trend plus a time trend to be interacted with the
‘to-be-treated’ dummy in the pre-treatment period 2007-2009. The results in the Appendix
Table A6 demonstrate that the treatment group does not reveal any statistically significant
difference in the trend from the control in the years prior to treatment for our variables of
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interest.10 Stillbirths and 28-365 days mortality decline more slowly on average in treated
than in untreated regions, pointing out at that the to-be-treated regions are actually doing
worse in some dimensions, but importantly, not in the dimensions we are interested in
measuring.11
The risk of endogenous treatment might still not be showing up in the pre-trends: good
oblast effect may not be internalized in observed mortality unless the oblast is treated.
Selected oblasts could be responding better to treatment and that could be the very reason
they were selected. In this case it is impossible to estimate an ATE, since the selection
variable is not independent or conditionally independent of the unobserved random variable
that causes the heterogeneity in the response to treatment (Wooldridge, 2010, p.910).
However, we address the possible selection biases outlined above, when we run our base-
line model on a subsample of the regions (54) that are treated plus the regions that are
selected for treatment in 2013-2017. In this case, our control group is more likely to both
satisfy the DD identification condition by being more similar to the treatment group in
terms of all observed criteria for selection and the unobserved ‘need’ and ‘ability’ of the
region to maintain a high-tech centre. Both groups are likely to respond to treatment more
similarly. We acknowledge, however, that the issue of which oblasts get treated first and
which get treated last still stands, but concerns of unobserved differences and possible bias
that may be caused by them are much milder.12 We thus use this specification as our
preferred model, as it is the most conservative one possible given the capacity of our data.
We also apply all diagnostic tests above to this subsample of 54 regions and they all still
hold.
We additionally test for the possibility that mothers are crossing regional borders to be
treated in the center, which can cause contamination of control group, and find no evidence
of such occurrence at a noticeable scale.13
10In this estimation we exclude Omsk, as it was treated in 2009, and we need at least 3 periods to test for
differential trends.
11We also try a specification with one and two period policy lead variables included into our set of controls. lead1
and lead2 indicate the policy status one and two periods before the opening of the perinatal center in the treated
regions, as in Frakes (2013) and Acemoglu and Finkelstein (2008). We use them to demonstrate that the opening of
the center is not associated with some other socio-economic programs in the area that could have been improving
health outcomes before the center was introduced. However, the coefficients on these variables are not significant
(Online Appendix Tables 3 and 4), so we are less worried about the true impact of a perinatal center.
12Another way to ‘purge’ the potential endogeneity is to use an instrument orthogonal to the error components
and that affects mortality only through the increased probability of selection. Ties of the local governor to Kremlin
increase the probability of selection, but arguably do not affect infant mortality directly, hence a proxy of connection
to the federal government can be a candidate for the instrument. We hypothesized that a good proxy could be years
of the governor in power as a measure of connection, but failed to get significant first stage.
13In Table 5 of the Online Appendix the births count neither changes significantly in the treated regions after
treatment, nor does it change in the neighboring regions after treatment. This shows that there is no evidence of
mothers giving births in the neighboring treated regions and improving the control regions’ statistics, thus biasing
our effect downwards. We also do not find an effect if we interact a perinatal dummy with an indicator of being close
to the border.
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VI. Results
A. Main Findings
Table 1—Effect of Perinatal Center Opening on Infant Mortality, OLS
(1) (2) (3) (4) (5) (6)
0-1 yr
Mortality
0-28 days
Mortality
0-6 days
Mortality
Perinatal Losses Stillbirths
28-365 days
Mortality
Perinatal Center -0.582∗∗∗ -0.451∗∗ -0.293∗∗ -0.533∗∗ -0.241 -0.130
(0.211) (0.177) (0.141) (0.238) (0.197) (0.109)
Income per Capita, in 1000 rub -0.0186 -0.0176 -0.00792 0.0613 0.0694 -0.00103
(0.122) (0.0692) (0.0511) (0.0756) (0.0485) (0.0587)
Alcoholism (per 1000 population) 0.113 0.173 0.0960 0.322 0.233 -0.0600
(0.528) (0.378) (0.303) (0.518) (0.292) (0.212)
Healthcare Financing, in 1000 rub 0.0419 0.0350 0.00993 0.0554 0.0452 0.00692
(0.0259) (0.0220) (0.0162) (0.0380) (0.0338) (0.0281)
Percent of Urban Population -0.0418 -0.0675 -0.104 -0.0952 0.00895 0.0257
(0.1000) (0.0887) (0.0691) (0.0745) (0.0672) (0.0607)
Observations 581 581 581 581 581 581
R2 0.276 0.286 0.249 0.417 0.407 0.127
OblastFE Yes Yes Yes Yes Yes Yes
TimeFE Yes Yes Yes Yes Yes Yes
OblastTimetrend No No No No No No
Standard errors in parentheses
Errors clustered at oblast level
∗ p < 0.10, ∗∗ p < 0.05, ∗∗∗ p < 0.01
Results suggest that the introduction of perinatal centers reduced infant mortality via
saving lives soon after birth. Tables 1 and 2 show results of Model (1) on full sample
and sample with to-be-treated controls respectively. We prefer the latter sample, Table
2, because we are wary of the fact that there may be a selection on unobservables that
could lead to biased estimates. Infant mortality drops by 0.391 deaths per 1000 live births,
or by 3.8 percent relative to the baseline mortality rate in 2007 (9.11 deaths per 1000
infants). Neonatal mortality (0-28 days) is reduced by 0.401 deaths per 1000 live births,
which constitutes a 6.9 percent average reduction from the baseline rate of 5.5 deaths per
1000 births; mortality in 0-6 days after birth declines by 0.287 deaths per 1000 live births
(or 7.3 percent on average from 3.750 deaths per 1000 births) due to a perinatal center
introduction. These numbers suggest that 8-9 fewer infants die in the mean oblast with
23,300 births each year. As expected, the proportional effect on earlier mortality is larger.
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Table 2—Specification with To-Be-Treated Control Group
(1) (2) (3) (4) (5) (6)
0-1 yr
Mortality
0-28 days
Mortality
0-6 days
Mortality
Perinatal Losses Stillbirths
28-365 days
Mortality
Perinatal Center -0.391∗ -0.401∗∗ -0.287∗ -0.429 -0.140 0.0103
(0.198) (0.185) (0.157) (0.281) (0.209) (0.0929)
Income per Capita, in 1000 rub -0.000581 -0.00891 0.0205 0.0421 0.0249 0.00833
(0.0615) (0.0545) (0.0562) (0.0839) (0.0543) (0.0279)
Alcoholism (per 1000 population) -0.260 0.0140 -0.000911 -0.182 -0.181 -0.274
(0.518) (0.409) (0.380) (0.558) (0.296) (0.202)
Healthcare Financing, in 1000 rub -0.0185 -0.000792 -0.000367 0.0116 0.0108 -0.0177
(0.0379) (0.0219) (0.0165) (0.0287) (0.0218) (0.0209)
Percent of Urban Population -0.00353 0.0410 -0.0237 -0.117 -0.0903 -0.0445
(0.100) (0.115) (0.0826) (0.113) (0.102) (0.0501)
Observations 378 378 378 378 378 378
R2 0.443 0.373 0.318 0.449 0.434 0.303
OblastFE Yes Yes Yes Yes Yes Yes
TimeFE Yes Yes Yes Yes Yes Yes
OblastTimetrend No No No No No No
Standard errors in parentheses
Errors clustered at oblast level
∗ p < 0.10, ∗∗ p < 0.05, ∗∗∗ p < 0.01
We see the smallest, but still significant effect of a perinatal center’s presence on total infant
mortality. As for Table 1, we find that the magnitude of the coefficient on the two early
mortality rates is almost the same as in a more conservative model, but the coefficient on
infant mortality doubles. This shows that the declining trend for infant mortality in treated
regions compared to any other region is likely steeper than that compared to regions that
will receive treatment in the next stage of the project.
The stillbirths rate declines insignificantly. With vast shifts in live birth/late abortion
criteria, stillbirths are likely to have increased in many regions to offset a decline in the
possibility of using late abortions as means of undercounting, and this may have happened
regardless of the presence of the perinatal center.
Interestingly, postneonatal mortality does not change at significant levels. We know that
the risk of death for LBW and prematurely-born infants is highest in the first week and
month of life and it varies highly with the availability of technology. For infants with
average weight and gestation the risk of death is more uniformly distributed throughout
the first year of life and more likely to vary due to a number of different inputs, such
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Table 3—Sequential Effect of Perinatal Center Opening on Mortality, OLS
(1) (2) (3) (4) (5) (6)
0-1 yr
Mortality
0-28 days
Mortality
0-6 days
Mortality
Perinatal Losses Stillbirths
28-365 days
Mortality
Year 1 after opening -0.240 -0.388∗∗ -0.277∗∗ -0.446∗∗ -0.159 0.148
(0.216) (0.184) (0.132) (0.193) (0.146) (0.122)
Year 2 after opening -0.540∗ -0.464∗ -0.391∗ -0.457 -0.0713 -0.0753
(0.273) (0.241) (0.202) (0.375) (0.281) (0.132)
Year 3 after opening -0.525∗ -0.347 -0.151 -0.366 -0.218 -0.178
(0.291) (0.273) (0.255) (0.569) (0.463) (0.208)
Observations 378 378 378 378 378 378
R2 0.447 0.378 0.330 0.453 0.437 0.313
OblastFE Yes Yes Yes Yes Yes Yes
TimeFE Yes Yes Yes Yes Yes Yes
OblastTimetrend No No No No No No
Controls Yes Yes Yes Yes Yes Yes
Standard errors in parentheses
Errors clustered at oblast level
∗ p < 0.10, ∗∗ p < 0.05, ∗∗∗ p < 0.01
as good care, clean environment and timely doctor’s diagnoses.14 We thus can consider
postneonatal category of mortality effectively as a placebo group that less depends on
available technology. We are more confident that it is the change in access to equipment in
the healthcare production function that is having an effect, as we see that only the early
mortality groups are affected. This further confirms that our results are not driven by
more general changes that improve health outcomes, other than the improved access to
technology.
Table 3 represents a sequential effect of the perinatal center. These results are shown
only for the first three years, since no other treated region except Omsk opened a sufficient
number of years ago for us to have outcomes four and five years after opening. Even for
three years after opening we are considering just four treated regions, so some loss of power
is expected. The effect on all three mortality groups of interest (0-6, 0-28 days and 0-1 year
mortality) is larger in the second year after opening, as anticipated, since it takes time for
the doctors in the center to work out the best practices and get used to the new building
and equipment. We witness this result also possibly due to some centers opening later in
spring, while the treatment dummy is assigned as one for that first year, underestimating
the full effect during the year of a center’s opening.
14Dmitry Nikolaevich Degtyarev, telephone conversation with the author, Dzhamilya Nigmatulina, May, 2015
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The reduction in all groups of mortality is comparable to the reduction of neonatal
mortality in Argentina from improved water facilities of 0.226 from the mean of 2.3 deaths
per 1000 live births, which is 11 percent (Galiani, Gertler and Schargrodsky, 2005), but
significantly smaller than those from randomized policies in India and Tanzania (which
is easily explained by diminishing marginal returns of mortality being relatively lower in
Russia than in Tanzania). Hovever, the US evidence from admission to NICU due to
marginally smaller weight enabling an infant meet the admission criteria reduces 0-7 day
mortality by 16 percent, 0-28 day mortality by 23 percent and one year mortality by 17
percent(Almond et al., 2010), which is higher than what we find in Russia. Finally, Nizalova
and Vyshnya (2010) also demostrate a much higher savings of 2.1 lives per 1000 births, vs.
0.391 lives per 1000 births in our study. Of course, to a large extent this difference may
reflect more dire initial conditions in Ukraine.
B. Additional Considerations
Opening of a center can cause other processes to take place that also indirectly affect
mortality in some cases. One such process is diversion of resources from other facilities
or their closure. Another change is new centers inviting doctors from other regions to
fill in new places. Such processes playing out at the same time as treatment can reduce
or increase the effect attributed to the center. Further, there could be differences in the
influence of the new center on mortality depending on whether the hospital was built from
scratch or the new facility was annexed to the existing hospital. Finally, the change in
mortality could be smaller if other advanced maternity facilities already existed in a given
region, so mothers have had some access to high-tech care.
First, we test whether the effect of perinatal centers differs when facilities for complicated
deliveries already existed in the region before (even if not as advanced), as opposed to the
effect from just introducing the complicated delivery care for the first time. We thus add
an interaction term β2Pr,t ∗ NoExist to our main specification (4), where NoExistrt is
an indicator for whether the new hospital was the first high-tech delivery facility in the
region. In the resulting Appendix Table A7, we see no difference in responses to treatment
for 0-6, 0-28 days and 0-1 year mortality. However, there is a significant reduction of
stillbirths and of perinatal mortality. This is intuitive, as the difficulty to perform proper
and timely diagnostics in simple maternity hospitals affects the likelihood of fetuses to have
been stillborn, and there is a significant improvement once an advanced facility opens.
(4) Mr,t = β0 + β1Pr,t + β1 + β2Pr,t ∗NoExistrt + φZrt + λt + γr + εr,t
We run the same regression as (4) but now interact the treatment with an indicator of
whether the hospital has been built from scratch or as part of the existing hospital (Ap-
pendix Table A8). Except perinatal losses dropping significantly more in regions where the
new facility did not belong to a larger existing hospital, there is no significant difference in
treatment effect along this dimension. The regions with a large existing hospital that an-
nexed the center tend to be slightly better off than those where it is built as a stand-alone
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facility, so this additional reduction in perinatal losses in the latter group stems from the
fact that it possibly had some more avertable perinatal losses before treatment.
Regional governments may optimize by redirecting resources from other facilities in the
region, which, if true, on the one hand means that fewer lives are saved, but on the other
hand, that these lives are saved at a lower overall cost. We measure the substitution
effect with counts of simple maternity units and maternity hospitals, expecting some of
these facilities to close after perinatal center opens.15 We find that even though some
maternity hospitals do close, there is no compelling evidence that the substitution effect
accompanying the perinatal center openings has a significant impact on mortality.
If neonatologists, Ob Gyn doctors and midwives (both counts and provision) are attracted
to the treated regions, mortality can be expected to drop further, which can blur the effect
attributed to the high-tech equipment. However, reassuringly, none of the relevant types
of doctors increased in the treated regions after Perinatal Center opening at statistically
significant levels.16
Finally, there is one remaining concern: out-of-pocket medical payments are prevalent in
Russia. It could be that richer (and thus maybe healthier) mothers are more likely to get
themselves into the NICU hospital and get treated, so this can overestimate the treatment
effect. If this effect is important, it should lead to improvements in urban (richer) birth
outcomes, but not rural (poorer) birth outcomes. We only could find the disaggregated data
of infant mortality by urban and rural areas and for a subset of regions; we analyze these
data in Table A9. Surprisingly, in the rural populations’ mortality decreases significantly
more, so it is likely that re-routing of births from remote areas does, indeed, take place,
and out-of-pocket payments are at least not so severe as to completely offset this re-routing
effect.
C. Cost-benefit analysis
Considering large monetary investments into the perinatal centers without an a priori
obvious return, a cost-benefit analysis is imperative for policy evaluation and comparison
with other interventions (for instance, with the return on Mother and Infant Project in
Ukraine (Nizalova and Vyshnya, 2010)). We do two types of evaluations: a rate of return
over the lifetime of a hospital (taken to be 40 years), and an estimation of a cost per life
15Tests for a substitution effect are included in Online Appendix, Table 6. The number of maternity hospitals
indeed decreased with treatment, so we presume that some of the investment was done ‘at the expense’ of old basic
hospitals. As for mortality outcomes of the perinatal center interacted with the maternity hospital count, Online
Appendix Table 7 shows that neonatal mortality does not fall significantly more with higher count of maternity
hospitals after treatment.
16Results are included in Appendix Table 6 of the Online Appendix. The coefficients on midwives and neonatol-
ogists are positive, yet not significant. If we interact the change in neonatologists in the first year of treatment with
the Perinatal Center dummy (Table 9 in the Online Appendix), we see that the larger is the increase in neonatologists
in the first year of treatment, the smaller is the reduction in mortality. More variation is necessary to derive firmer
conclusions, but it seems that the arriving neonatologists (and it is most plausible they go to work at the new center)
need to acquire skills with the new equipment: the transition period thus may avert fewer deaths than the treatment
in places where the specialists are locals.
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Table 4—Cost Comparisons of Different Health Interventions
Incremental cost for QALY As quoted In 2014 dollars
Our estimate, high-tech neonatal care, 2014 PPP $ 44,900 21,412
Cutler and Meara (2000), Neonatal care (US, 1990), $ 3,726 6,065
Cutler and Meara (2000), Prenatal care (US, 1990), $ (4,214)(Cost Savings) (6859) (Cost Savings)
Cutler and Meara (2000), Influenza vaccinations <3 years (US, 1990), $ 1,745 2,840
Cutler and Meara (2000),Coronary arthery bypass (US, 1990), $ 33,600-48,300 54,700-78,700
Cutler and Meara (2000), Severe hypertension treatment (US, 1990), $ 17,000 27,700
Cutler and Meara (2000), Pap Smear every 3 years for ages 20-74, $ 17,000 27,700
Mangham-Jefferies et al. (2014), Promoting hospital-based
breast-feeding (Honduras, 1993), $
164 (per DALY averted) 249
Mangham-Jefferies et al. (2014), Outreach obstetrics units, referral
assistance, tratining birth assistants (The Gambia, 1991), $
148-620 (per LY) 153-640
Cost per life saved
Our estimate, high-tech neonatal care, 2014 PPP $ 2,619,000 1,380,000
Mangham-Jefferies et al. (2014), Promoting hospital-based
breast-feeding (Honduras, 1993), $
6,894 7,120
Mangham-Jefferies et al. (2014), Outreach obstetrics units, referral
assistance, tratining birth assistants (The Gambia, 1991), $
1,380-6,414 1,400-6,625
Mangham-Jefferies et al. (2014), Teutanus Toxoid immunizaiton
(Indonesia, 1985), $
1,564 1,615
Almond et al. (2010), Neonatal intensive care (US, 1983-2002), $ 527,083-615,270 566,000-660,650
saved or per incremental year of life in order to compare our finding to other studies.17 For
either measure we use interest rate, an estimate of operational costs, and capital cost data.
For capital costs we use an average capital investment of a perinatal center (2.064 bln rb
or $103.2 mln in 2014 PPP USD). Operational cost is derived from the fact that most
centers range between 130 -190 beds, and the number of people employed range between
600 (Kurgan) and 900 (Tomsk), but employee information was only available for a few
hospitals. Taking 600 as a lower bound, and information on average wages of healthcare
workers from Rosstat, we assume that doctors, nurses and junior nurses work in the center
in equal proportions and find that a hospital on average needs to pay around 213 million rb
in wages yearly. Adding a 5.4 percent required health insurance and 30 percent typically
allocated maintenance cost on top of the wages, we assume operational cost to be 320
million rb, or (16 million 2014 USD in PPP).18 We convert the yearly costs and benefits
to present value terms utilizing the Central Bank of Russia’s discount rate of 8.25 percent
for 2012 (stavka refinansirovaniya) Adjusting the future cash flows by Russia’s average
inflation of 7 percent, the real interest rate becomes 1.25 percent.
In order to monetize the lives saved by a new perinatal center, we can turn to the expert
estimates of Value of Statistical Life (VSL) in Russia. Guriev (2011) suggests the VSL to
17The lifetime of a hospital is chosen according to the expert opinion of Guzel Ernstovna Ulumbekova, email
message to the author (Nigmatulina), 04 Oct, 2015
18The choice of 30 percent markup is fair according to the expert opinion of Guzel Ernstovna Ulumbekova, email
message to the author (Nigmatulina), 04 Oct, 2015
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be in the 60-135 mln rb ($2-4.5 mln) range. Bykov (2007) offers a slightly smaller, but
comparable estimate, 50 mln rb, or $1.6 mln in 2014 dollars. We also calculate our own
VSL to the government by dividing the GDP by working age population and multiplying
by 43 years of expected working life to get 36 mln rb. We finally multiply the VSL with
the newborn lives saved per year in a region and subtract the estimated average annual
cost for a perinatal center.
We recognize that the resulting returns to investment are sensitive to the VSL and the
interest rate chosen, which is why we provide sensitivity analyses, varying different VSLs
and interest rates (Appendix Tables A11 and A12). In order to get a very small positive
return of one percent, VSL needs to be 50 mln, or the region needs to have more than
30,000 births. Using our own VSL we find that an average perinatal center has a return to
investment of negative 15 percent in a region with 23,292 yearly births (the average from
2013). Similarly, in Appendix Table A12 we see that keeping the VSL at 36 million rb,
and for an average region with 30,000 births, the return to a perinatal center varies from
one percent (for 3.5 percent discount rate) to nine percent (for 1.25 percent discount rate).
We also assume that infants surviving past 1 year of life have an average life expectancy
and quality.
However, it is important to note that estimating these benefits is done without consider-
ing any health benefits to the mother and better morbidity outcomes for infants who would
not have died in the absence of treatment. Nevertheless, using just measurable lives saved
is the standard procedure in the literature: for example, Nizalova and Vyshnya (2010)
do not explicitly consider morbidity in their benefits estimation, so the comparison of our
results to theirs is accurate.
Nizalova and Vyshnya (2010) find that the Mother and Infant Project in Ukraine gen-
erated 962 percent return accounting for the lives saved, which is in a much higher range
than the returns in Russia, especially considering a much more conservative use of VSL
for Ukraine: if Russian values were used, the return would be even higher. Such evi-
dence points out that there could be other ways to avert deaths in Russia, with a much
smaller investment, though the difference also reflects the dire state of healthcare funding
in Ukraine.
Estimating the cost per life saved we first find that the perinatal centers altogether save
263 lives per year.19 Then we use an average investment cost of a perinatal center in a
region, annualized over 40 years using annualization formula (65,886,000 rb) plus the yearly
perinatal center costs (320,000,000) and divide the total cost by the number of estimated
lives saved in each region, as in Almond et al. (2010), and take the mean over all regions
to get the national value.20 The cost per life saved from our calculations is 52,153,000
rb (1,380,000 in 2014 USD or 2,619,000 in PPP 2014 USD). Regardless of which dollar
equivalent we choose, the value per live saved is significantly larger than that for the US
19To get this value we multiply all the births in the treated regions in 2013 (when all 24 centers were open) by
the reduction in mortality rate attributed to the centers (0.391 deaths per 1000 births from Table 2)
20Annualization formula used is d = P ∗ r/(1 − 1/(1 + r)T ), where P = 2, 064, 000, 000 is the average cost of
building a perinatal center, r = 0.0125 is the Bank of Russia interest rate net of inflation, T = 40 and is the upper
bound of a lifetime of a hospital
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quoted by Almond et al. (2010): $527,083-$615,270 in 2010.21 According to the Ukrainian
study, 5.63 lives are saved per maternity-year, costing the government 60,000 2005 USD
per maternity-year. This translates into 12,592 2014 USD per life saved, which is around
100 times cheaper than the high-tech investment in Russia.
To be able to compare to a few other studies we calculate the cost per quality-adjusted
life year (QALY). Since we do not have any information on quality of life conditional on the
weight of the newborn, we use estimations from Cutler and Meara (2000) assuming that all
lives saved are those of LBW newborns, and that in Russia in 2014 newborns of a certain
weight on average can expect to live a life of comparable quality as in the US in 1990,
and have the same longevity relative to the Russia’s average life expectancy. Knowing the
shares of different LBW categories in 2013 for Russia we estimate that on average a LBW
infant who survived to 1 year will live 58.3 QALY’s.22 In Table 4 we compare our findings
with costs for QALY or cost per life saved of various interventions from other studies. Our
cost per QALY finding stands as one of the highest on this list only surpassed by coronary
arthery bypass.
One possible explanation of the high-tech care being so unproductive given the cost is the
inefficiency with which the hospitals are run. The main component of cost of life saved is
operational expenses, rather than investment cost. This means that running these hospitals
is so expensive that they are expected to be saving more lives than they currently are. Poor
performance could arise from poorly qualified or unmotivated doctors and nurses, doctors
unable to use high-tech equipment, or bad hospital management. Additionally, centralized
high tech services in a vast country inherently will be inaccessible to many high risk moms.
VII. Conclusion
Investment in high-tech infrastructure reduces infant mortality in a middle-income coun-
try, but at a high cost. Building state-of-the-art hospitals in 24 out of 83 regions in Russia
reduced infant mortality rate by 3.8 percent on average (the rate drops by 0.0391 percent-
age points), but each life saved costed the government around 52 million rb (2.6 million
2014 PPP USD), which is higher than similar investments in the US. This demonstrates
that bottlenecks, such as institutional capacity to build hospitals at lower costs, or lack
of other quality inputs into healthcare, remain and restrict the potential effect from the
investment. The subject of the study is further relevant, as the federal government plans
to build centers in additional 30 regions, and it is important to accurately predict expected
mortality reductions from the investment. If the reduction of mortality is expected to be
the same as in the current part of the treatment, only the large regions with more than
30,000 births a year should expect a positive return, and only if a life is valued at 30 mln
rb or more.
At the same time, the regions that built a perinatal center in the last three years did
achieve the government-set target rates of early neonatal mortality that declined from 3.66
21We believe that PPP 2014 USD is most accurate numeraire for comparison with the US result, because it
represents the cost to the government in real terms.
22We are only considering cases of infants who survived their first year of life for this QALY calculation.
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to 2.9, compared to 3.82 to 3.24 (when the control group is regions “to-be-treated”). The
establishment of a perinatal center reduces infant mortality by saving babies in the first
week and in the first month of their lives. The largest reduction in the rate compared to
baseline rate in 2007 is for first week mortality (7.3 percent).
We address two major concerns with the validity of the results. First, the propensity of
the selected regions (in 2007) to benefit from the center may be higher than that of a usual
control region, so the DD estimate might exaggerate the treatment effect. We carefully
select the control group and only include regions that are subject to treatment in the second
stage of the policy. We further test for the pre-existing differences in the trends for the
treatment and control groups. Second, the degree of mortality underreporting could be
higher in the treated oblasts, since they have an incentive to demonstrate favorable effects
of the federal investment. We rule this concern out with diagnostic regressions on variables
that capture underreporting; namely terminations of pregnancy in 22-27 weeks of gestation
and proportion of births by birth weight.
It bears mention that our estimates of benefits are restricted to lives saved directly. To a
modest extent, then, the true returns of the perinatal center may be underestimated, since
the treatment in the center have very likely improved morbidity of mothers and infants
as well. In addition, the center should raise the overall obstetrics care quality in the
region by interacting with other hospitals, encouraging the dissemination of best practices,
and monitoring their performance in the long run. Unfortunately, we do not have any
information on improved morbidity or how to quantify it. Nevertheless, the investment
remains expensive when compared to similar studies in other countries, which also only
consider lives saved as their outcome measure.
The commitment of roughly 75 billion rb (3.8 billion 2014 USD in PPP) to creating
NICUs, along with still larger operation costs, is a major commitment by the Russian
Ministry of Health and has accounted for about 1/3 of the 2013 capital budget of 222.5
billion rb. As noted in Evans and Garthwaite (2012), $1.1 billion was spent in the US for a
comparative effectiveness research in the frame of the American Recovery and Reinvestment
Act that became law in 2009. Such a detailed research investment may be costly in a
country that may lack basic accessibility of care. However, when resources allocated to
healthcare are limited, comparing relative returns of major investment, such as Neonatal
Intensive Care Units, high-tech cardiac centers, or, increasing the number of beds in a large
number of hospitals, is absolutely necessary. Although the evidence is that the money spent
on Perinatal Centers’ project has yielded some returns, there may exist much higher returns
from addressing basic needs of current Russian healthcare system, such as increasing the
number and quality of maternity units accessible to those who live far from big centers.
Upper middle income countries will be making vast health infrastructure investments in
the near future and one should not underestimate the importance of informed choices to
achieve higher returns to healthcare.
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Appendix
A1. Tables
Table A1—Summary Statistics Full Sample
count mean sd min max
0-1 yr
Mortality
581 8.447761 3.03274 0 23.9
0-28 days
Mortality
581 4.883685 2.115317 0 18.1
0-6 days
Mortality
581 3.266017 1.712627 0 14
Perinatal Losses 581 8.610403 2.512963 0 19.9
Stillbirths 581 5.351271 1.505431 0 11.1
28-365 days
Mortality
581 3.564076 1.599954 0 17.9
Perinatal Center 581 .1153184 .3196811 0 1
Births, count 581 21871.61 19736.67 641 135853
Life Expectancy at Birth (yrs) 579 68.33382 2.870074 57.5 78.84
Income per Capita, in 1000 rub 581 17.40301 8.996022 4.0059 66.276
Healthcare Financing, in 1000 rub 581 8.047805 5.973791 1.7235 43.73544
Ob Gyn per 10000
wmn in fert age
581 5.135663 1.204077 2.8 10.02
Percent of Urban Population 581 69.26351 13.2023 26.7 100
Percent below Poverty Line 576 15.30972 5.333456 5.6 45.3
Maternity Hospital, count 581 2.156627 2.67902 0 19
Vodka Consumption
per Capita (litres per cap)
581 11.18373 4.261653 0 24.3
Neonatologists
per 1000 infants
581 32.20998 9.206235 0 61.4
Observations 581
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Table A2—Summary Statistics in 2007 (Before Treatment)
Never Treated To-Be-Treated Treated Total
0-1 yr
Mortality
10.42 9.307 9.599 9.773
(3.805) (2.909) (2.459) (3.132)
0-28 days
Mortality
5.750 5.503 5.497 5.586
(1.871) (2.424) (1.679) (2.021)
0-6 days
Mortality
3.933 3.823 3.658 3.812
(1.409) (1.942) (1.193) (1.558)
Perinatal Losses 9.450 9.130 9.148 9.244
(2.262) (2.419) (1.539) (2.120)
Stillbirths 5.506 5.333 5.486 5.437
(1.606) (1.033) (0.952) (1.227)
28-365 days
Mortality
4.670 3.803 4.102 4.187
(2.639) (1.213) (1.223) (1.847)
Births, count 11208 24027.2 23886.4 19608.7
(9930.0) (20881.4) (14561.4) (16918.4)
Life Expectancy at Birth (yrs) 65.90 67.69 66.65 66.78
(3.075) (2.776) (1.867) (2.735)
Income per Capita, in 1000 rub 11.96 11.27 10.34 11.23
(8.427) (6.349) (2.680) (6.369)
Healthcare Financing, in 1000 rub 7.491 5.001 5.059 5.868
(7.669) (3.287) (2.779) (5.201)
Ob Gyn per 10000
wmn in fert age
5.436 4.773 5.138 5.106
(1.407) (1.011) (0.854) (1.145)
Percent of Urban Population 67.14 68.56 72.90 69.34
(14.23) (12.60) (10.89) (12.79)
Percent below Poverty Line 20.30 16.05 16.50 17.63
(8.866) (5.134) (4.523) (6.724)
Maternity Hospital, count 1.643 2.367 3.292 2.390
(1.747) (3.764) (2.196) (2.810)
Vodka Consumption
per Capita (litres per cap)
12.86 11.87 12.46 12.38
(4.077) (4.277) (4.061) (4.117)
Neonatologists
per 1000 infants
32.90 29.73 35.99 32.64
(11.32) (7.478) (8.557) (9.486)
Observations 82
mean coefficients; sd in parentheses
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Table A3—Summary Statistics in 2013 (After Treatment)
Never Treated To-Be-Treated Treated Total
0-1 yr
Mortality
9.866 8.000 7.800 8.594
(4.415) (2.165) (1.515) (3.137)
0-28 days
Mortality
5.797 5.033 4.492 5.143
(2.626) (1.892) (1.013) (2.047)
0-6 days
Mortality
3.790 3.297 2.904 3.355
(2.259) (1.501) (0.765) (1.683)
Perinatal Losses 10.26 9.383 9.483 9.717
(2.775) (2.987) (1.506) (2.565)
Stillbirths 6.503 6.123 6.604 6.395
(1.536) (1.921) (1.399) (1.644)
28-365 days
Mortality
4.069 2.967 3.308 3.451
(3.178) (0.770) (0.909) (2.029)
Births, count 13552.7 28958.8 27977.4 23292.2
(12705.8) (28053.2) (18589.2) (21956.6)
Life Expectancy at Birth (yrs) 69.18 70.80 69.83 69.96
(2.934) (2.584) (1.815) (2.590)
Income per Capita, in 1000 rub 25.13 23.84 21.91 23.73
(13.84) (8.540) (4.755) (9.962)
Healthcare Financing, in 1000 rub 12.14 10.62 8.942 10.66
(8.581) (5.750) (1.675) (6.266)
Ob Gyn per 10000
wmn in fert age
5.396 4.761 4.998 5.051
(1.471) (1.056) (0.788) (1.175)
Percent of Urban Population 66.35 69.17 74.07 69.60
(15.20) (12.82) (10.25) (13.27)
Percent below Poverty Line 15.56 12.34 13.06 13.67
(6.582) (3.594) (3.038) (4.896)
Maternity Hospital, count 1.276 2 2.583 1.916
(1.334) (3.384) (2.244) (2.519)
Vodka Consumption
per Capita (litres per cap)
9.931 8.868 9.075 9.300
(4.404) (3.843) (2.977) (3.815)
Neonatologists
per 1000 infants
30.38 28.78 34.85 31.10
(10.41) (7.722) (6.816) (8.799)
Observations 83
mean coefficients; sd in parentheses
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Table A4—Regression with Full Controls
(1) (2) (3) (4) (5) (6)
0-1 yr
Mortality
0-28 days
Mortality
0-6 days
Mortality
Perinatal Losses Stillbirths
28-365 days
Mortality
Perinatal Center -0.367∗ -0.346∗ -0.280∗ -0.473 -0.195 -0.0212
(0.202) (0.189) (0.166) (0.292) (0.203) (0.0971)
Income per Capita, in 1000 rub 0.0191 0.0269 0.0381 0.0257 -0.0113 -0.00774
(0.0767) (0.0673) (0.0581) (0.0702) (0.0486) (0.0334)
Healthcare Financing, in 1000 rub -0.0144 -0.00495 -0.00124 0.0245 0.0250 -0.00944
(0.0362) (0.0238) (0.0168) (0.0293) (0.0268) (0.0179)
Ob Gyn per 10000
wmn in fert age
-0.0342 -0.0363 -0.199 -0.499 -0.314 0.00212
(0.218) (0.215) (0.258) (0.442) (0.283) (0.121)
Percent of Urban Population 0.00713 0.0286 -0.0537 -0.156 -0.100 -0.0215
(0.0866) (0.0950) (0.0714) (0.119) (0.0965) (0.0462)
Percent below Poverty Line 0.0165 0.0454 0.0289 -0.0270 -0.0580 -0.0289
(0.0680) (0.0723) (0.0463) (0.0579) (0.0418) (0.0262)
Maternity Hospital, count 0.0577 0.107 0.0328 -0.00665 -0.0483 -0.0496
(0.0765) (0.0691) (0.0526) (0.107) (0.0831) (0.0337)
Vodka Consumption
per Capita (litres per cap)
0.0440 0.0369 0.0473 0.0749 0.0286 0.00712
(0.0509) (0.0380) (0.0325) (0.0455) (0.0323) (0.0296)
Neonatologists
per 1000 infants
-0.0315 -0.0209 -0.00958 -0.0288 -0.0189 -0.0106
(0.0348) (0.0301) (0.0247) (0.0241) (0.0152) (0.0124)
Observations 378 378 378 378 378 378
R2 0.450 0.385 0.331 0.461 0.446 0.306
OblastFE Yes Yes Yes Yes Yes Yes
TimeFE Yes Yes Yes Yes Yes Yes
OblastTimetrend No No No No No No
Standard errors in parentheses
Errors clustered at oblast level
∗ p < 0.10, ∗∗ p < 0.05, ∗∗∗ p < 0.01
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Table A5—Adding Fixed Effects and Controls One-by-One
(1) (2) (3) (4) (5)
0-6 days
Mortality
0-6 days
Mortality
0-6 days
Mortality
0-6 days
Mortality
0-6 days
Mortality
Perinatal Center -0.379∗ -0.178 -0.304∗ -0.261∗ -0.279∗
(0.203) (0.123) (0.170) (0.149) (0.143)
Constant 3.168∗∗∗ 3.133∗∗∗ 2.950∗∗∗ 3.835∗∗∗ 11.00
(0.182) (0.0219) (0.0679) (0.0818) (8.767)
Observations 378 378 378 378 378
R2 0.011 0.006 0.317 0.630 0.636
Oblast FE No Yes Yes Yes Yes
Time FE No No Yes Yes Yes
Oblast Timetrend No No No Yes Yes
Controls No No No No Yes
Standard errors in parentheses
Errors clustered at oblast level
∗ p < 0.10, ∗∗ p < 0.05, ∗∗∗ p < 0.01
Table A6—Testing for Differential Trends, 24+30 Sample
(1) (2) (3) (4) (5) (6)
0-1 yr
Mortality
0-28 days
Mortality
0-6 days
Mortality
Perinatal Losses Stillbirths
28-365 days
Mortality
Overall Timetrend -1.307∗∗∗ -0.819∗∗ -0.455∗ -0.818∗∗ -0.389∗∗ -0.489∗∗∗
(0.384) (0.364) (0.268) (0.357) (0.184) (0.154)
Overall Timetrend X Treated 0.236 0.0192 0.0417 0.263 0.242∗ 0.217∗
(0.239) (0.220) (0.160) (0.221) (0.130) (0.111)
Observations 159 159 159 159 159 159
R2 0.448 0.376 0.355 0.424 0.277 0.234
Controls Yes Yes Yes Yes Yes Yes
Oblast FE Yes Yes Yes Yes Yes Yes
Year FE Yes Yes Yes Yes Yes Yes
Standard errors in parentheses
Errors clustered at oblast level; Omsk region excluded because treatment happened in 2009
∗ p < 0.1, ∗∗ p < 0.05, ∗∗∗ p < 0.01
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Table A7—Response to Treatment if High-Tech Facilities Already Exist (in 11 treated regions)
(1) (2) (3) (4) (5) (6)
0-1 yr
Mortality
0-28 days
Mortality
0-6 days
Mortality
Perinatal Losses Stillbirths
28-365 days
Mortality
Perinatal Center -0.288 -0.299 -0.128 0.210 0.340∗ 0.0103
(0.243) (0.212) (0.170) (0.279) (0.199) (0.109)
Perinat Center X
No High-Tech Exists
-0.125 -0.249 -0.329 -1.346∗∗∗ -1.000∗∗∗ 0.124
(0.351) (0.352) (0.273) (0.288) (0.277) (0.156)
Observations 378 378 378 378 378 378
R2 0.445 0.375 0.323 0.470 0.458 0.311
OblastFE Yes Yes Yes Yes Yes Yes
TimeFE Yes Yes Yes Yes Yes Yes
OblastTimetrend No No No No No No
Controls Yes Yes Yes Yes Yes Yes
Standard errors in parentheses
Errors clustered at oblast level
∗ p < 0.10, ∗∗ p < 0.05, ∗∗∗ p < 0.01
Table A8—Allowing for Differential Effects if the Center is one of 9 Centers Built From Scratch
(1) (2) (3) (4) (5) (6)
0-1 yr
Mortality
0-28 days
Mortality
0-6 days
Mortality
Perinatal Losses Stillbirths
28-365 days
Mortality
Perinatal Center -0.412∗ -0.407∗ -0.195 -0.114 0.0814 -0.00480
(0.227) (0.212) (0.172) (0.282) (0.215) (0.106)
Perinat Center X
Built from Scratch
0.194 -0.00678 -0.229 -0.788∗ -0.534 0.201
(0.362) (0.365) (0.306) (0.468) (0.380) (0.153)
Observations 378 378 378 378 378 378
R2 0.445 0.373 0.320 0.456 0.440 0.312
OblastFE Yes Yes Yes Yes Yes Yes
TimeFE Yes Yes Yes Yes Yes Yes
OblastTimetrend No No No No No No
Controls Yes Yes Yes Yes Yes Yes
Standard errors in parentheses
Errors clustered at oblast level
∗ p < 0.10, ∗∗ p < 0.05, ∗∗∗ p < 0.01
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Table A9—Difference between Urban and Rural Areas
(1) (2)
Infant Mortality Urban Infant Mortality Rural
Perinatal Center -0.227 -0.617∗
(0.324) (0.360)
Oblast FE Yes Yes
Time FE Yes Yes
Controls Yes Yes
Observations 357 357
R2 0.850 0.747
Standard errors in parentheses
Errors clustered at oblast level. Urban and rural mortality missing for Khanty-Mansi, Nenets and Yamalo-Nenets autonomous regions
∗ p < 0.10, ∗∗ p < 0.05, ∗∗∗ p < 0.01
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Table A10—Cost-Benefit Analysis of a Perinatal Center in an Average Region
Benefits
Lives Saved
Average births in an oblast in 2013 23,292
Average lives saved (average births times 0.391 reduction in infant mortality) 9.11
Value of Life
GDP , mln rb 71,406,400
Working age population, count 85,161,578
GDP per worker, rb 838,481
Livetime work duration (ages 16-59), years 43
Value of Life (multiplying work duration by GDP per worker), mln rb 36
Present Value Benefits (over 40 years’ lifetime of a hospital), mln rb 10,286
Costs
Operational
Average Monthly Wage of Doctors and Nurses, rb 29,557
Yearly Wages of 600 Workers (conservative value), mln rb 213
Yearly Wages with Additional 5.4% OMS (workers’ insurance), mln rb 224
Maintenance (30% on average from yearly wages), mln rb 320
Present Value of Future Operational Costs, mln rb 10,038
Investment
Total Capital Investment per Center, mln rb 2,064
Present Value Total Costs, mln rb 12,102
Interest rate (Bank of Russia avg interest rate to non-finance
organizations in roubles for more than 3 yrs)
8.25%
Discount Rate Adjusted for Average Inflation of 7% 1.25%
Present Value Factor for Future Income Flow of 40 Years 0.04
Net Present Value, mln rb -1,816
Percent Return -15.00%
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Table A11—VSL Sensitivity Analysis of Returns to a Perinatal Center
Number of Births in a Region
1,000 10,000 15,000 20,000 30,000 40,000 50,000 70,000 90,000 100,000 130,000
V
S
L
,
m
il
li
o
n
rb
20 -98% -80% -70% -60% -39% -19% 1% 42% 82% 102% 163%
25 -97% -75% -62% -49% -24% 1% 27% 77% 128% 153% 229%
30 -97% -70% -54% -39% -9% 21% 52% 113% 173% 204% 295%
35 -96% -65% -47% -29% 6% 42% 77% 148% 219% 254% 361%
40 -96% -60% -39% -19% 21% 62% 102% 183% 264% 305% 426%
45 -95% -54% -32% -9% 37% 82% 128% 219% 310% 355% 492%
50 -95% -49% -24% 1% 52% 102% 153% 254% 355% 406% 558%
55 -94% -44% -17% 11% 67% 123% 178% 290% 401% 457% 624%
60 -94% -39% -9% 21% 82% 143% 204% 325% 447% 507% 689%
65 -93% -34% -1% 32% 97% 163% 229% 361% 492% 558% 755%
70 -93% -29% 6% 42% 113% 183% 254% 396% 538% 608% 821%
75 -92% -24% 14% 52% 128% 204% 280% 431% 583% 659% 887%
80 -92% -19% 21% 62% 143% 224% 305% 467% 629% 710% 953%
Table A12—Discount Rate Sensitivity Analysis
Number of Births in a Region
D
is
co
u
n
t
R
at
e
1,000 10,000 15,000 20,000 30,000 40,000 50,000 70,000 90,000 100,000 130,000
1.25% -96% -64% -45% -27% 9% 46% 82% 155% 228% 265% 374%
1.50% -96% -64% -46% -28% 9% 45% 81% 153% 226% 262% 371%
1.75% -96% -64% -46% -28% 8% 44% 80% 151% 223% 259% 367%
2.00% -96% -64% -47% -29% 7% 42% 78% 149% 220% 256% 363%
2.25% -96% -65% -47% -29% 6% 41% 77% 147% 218% 253% 359%
2.50% -96% -65% -47% -30% 5% 40% 75% 145% 215% 250% 355%
2.75% -97% -65% -48% -31% 4% 39% 74% 143% 212% 247% 351%
3.00% -97% -66% -48% -31% 3% 38% 72% 141% 210% 244% 347%
3.25% -97% -66% -49% -32% 2% 36% 71% 139% 207% 241% 343%
3.50% -97% -66% -49% -32% 1% 35% 69% 137% 204% 238% 339%
3.75% -97% -67% -50% -33% 0% 34% 67% 134% 201% 235% 335%
4.00% -97% -67% -50% -34% -0% 33% 66% 132% 199% 232% 332%
4.25% -97% -67% -51% -34% -1% 32% 64% 130% 196% 229% 328%
4.50% -97% -67% -51% -35% -2% 30% 63% 128% 193% 226% 324%
4.75% -97% -68% -52% -35% -3% 29% 61% 126% 191% 223% 320%
5.00% -97% -68% -52% -36% -4% 28% 60% 124% 188% 220% 316%
5.25% -97% -68% -52% -37% -5% 27% 58% 122% 185% 217% 312%
5.50% -97% -69% -53% -37% -6% 26% 57% 120% 183% 214% 308%
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A2. The Visual
We plot a range of graphs for all our outcome variables and observe the changes in trends
during policy implementation. We indicate the two larger policy changes in 2011 and 2012
with red vertical lines. For a more natural exposition, each year’s marker is put at the end
of the year (that is, 2012 data are shown at the start of 2013), for all our outcome variables
are year-end totals. Infant mortality data are presented in Figure A1.
Figure A1. Mortality Trends
Figure A1 shows three key mortality outcomes for live born infants (measured by the
mortality rate per 1000 live births). Trends in mortality are parallel and declining in both
groups, prior to treatment. After 2011 and 2012 the trends diverge: as the control group
rates increase on average, the treatment group rates continue to fall. After 2012, the
mortality rate increases for both groups due to the change in birth accounting standards.
